

HAEMONETICS CORP

NYSE: HAE
Industry: Health Care Equipment & Supplies

SABRIENT
BUY
RATING

Stock Fundamentals as of May 18, 2009

Sabrient Rating	Buy
Ticker	HAE
Market Cap Designation	Mid-cap
Market Capitalization (Billions)	\$1.4
Price	\$53.09
52-Week High/Low	\$67.49/46.78
EPS (TTM)	\$2.27
P/E Ratio (TTM)	23.4
Dividend Yield	0.0%
S&P 500 P/E Ratio	20.9
Price/Book Ratio	2.5
Price/Sales Ratio	2.3
30-Day Average Volume (Thousands)	360.6
Beta	0.26
Current Ratio	4.5
Short Interest Ratio	3.1
Shares Outstanding (Millions)	25.4

Sabrient Ratings

Sabrient's Buy/Hold/Sell ratings are based on a combination of dynamic filters that determine which attributes of a stock are most predictive in the prevailing market and which stocks best reflect those attributes but are not yet rewarded.

Sabrient starts with an "extraction" process that uses the best performing filters to identify stocks having certain compelling attributes currently sought by the market. Then, a composite scoring process uses a weighted average of several key scores to quantify the relative likelihood of upside or downside price action. As a result, the Buy/Hold/Sell rating may, in certain cases, seem inconsistent with a simple average of the scores cited in this analysis.

A BUY rating means the stock is expected to outperform its relevant benchmark substantially over the next 6 months. A SELL rating means the stock is expected to underperform its relevant benchmark substantially over the next 6 months. A HOLD rating means the stock is expected to perform in line with its relevant benchmark over the next 6 months.

If a stock is rated HOLD, the investor should review the stock's history of Sabrient ratings to see if it has recently changed to HOLD from BUY or SELL. If so, this indicates one of the following: (1) there has been a significant change in the stock's fundamentals, (2) the stock is already appropriately rewarded or punished by the market, or (3) there simply has been some recent price consolidation that warrants attention. A reading of Sabrient's analysis should identify which it is.

More about Sabrient on Page 4

Sabrient's Market Cap Designations


Large Cap	> \$5.0 Billion
Mid Cap	\$1.0 - \$5.0 Billion
Small Cap	\$150 Million - \$1.0 Billion
Micro Cap	< \$150.0 Million

Report prepared on **May 20, 2009** Page 1

Please see important disclaimer on page 5 of this report.

Copyright ©2009 Sabrient Systems LLC. All rights reserved.

HAEMONETICS CORP



Company Profile

Haemonetics Corporation designs, manufactures, and markets automated blood processing systems and single use consumables for blood donors and surgical patients.

Earnings and Revenue Update: For the quarter ended March 31, 2009, Haemonetics reported earnings of \$13.9 million or \$0.53 per share compared with \$16.2 million or \$0.62 per share for the prior quarter and \$13.8 million or \$0.52 per share for the same quarter one year ago. Revenues were \$152.4 million for the quarter ended March 31, 2009 compared with \$155.4 million for the prior quarter and \$138.7 million for the same quarter one year ago. Last twelve months' earnings were \$2.27 per share compared with \$1.94 per share a year ago. Last twelve months' revenues were \$597.9 million compared with \$516.4 million a year ago.

Sabrient Analysis

HAE exhibits the attributes that are currently being rewarded by the market and therefore receives a Buy rating.

- **Growth:** HAE's growth prospects are well above average, as reflected in a Sabrient Growth Score of 75.1. This score signifies favorable EPS trends.
- **Value:** The stock is likely to be considered fully valued or possibly overvalued based on its Sabrient Value Score of 36.0.
- **Momentum:** HAE receives a Sabrient Momentum Score of 17.6, which puts it among the lowest Sabrient momentum rankings. The score is a composite measure of price, earnings and group momentum.
- **Timeliness:** HAE has a Sabrient Timeliness Score of 16.8. This is a composite measure of short-term and long-term price performance and long-term group performance.


Sabrient Analysis continued on Page 3

Sabrient
Leaders In Investment Research

Current Sabrient Scores Compared with Industry and Relevant Benchmark


These Sabrient scores compare various aspects of HAEMONETICS CORP with its industry and relevant benchmarks. The scores are percentile rankings from 0 to 99.9. Higher scores are better. We use a weighted average of several key scores to quantify the relative likelihood of upside or downside price action. Therefore, the Sabrient rating may seem inconsistent with a simple average of the scores cited in this analysis.

Growth Score: 75.1




The Sabrient Growth Score reflects a company's historical and projected earnings growth, revenue and sales growth, projected cash flow, analyst activity, and changes in earnings estimates, each over various time periods. The higher the score, the better the combined performance of these key measures. With a Sabrient Growth Score of 75.1, Haemonetics is marginally higher than the average of its industry group, which has a Sabrient Growth Score of 72.2.

Value Score: 36.0




The Sabrient Value Score measures the relationship between a company's stock price and its intrinsic value, as indicated by earnings and balance sheet attributes, with an emphasis on earnings. Also considered are cash flow measures and fundamental valuation ratios. With a Sabrient Value Score of 36.0, Haemonetics is moderately lower than the average of its industry group, which has a Sabrient Value Score of 52.8.

Momentum Score: 17.6




The Sabrient Momentum Score measures a company's earnings and price momentum, evenly weighted, and augmented by group strength, money flow, and relative volume. Core technical factors include current price relative to periodic highs and moving averages. With a Sabrient Momentum Score of 17.6, Haemonetics is considerably lower than the average of its industry group, which carries a Sabrient Momentum Score of 38.6.

Earnings Score: 60.5




The Sabrient Earnings Score assesses a company's overall earnings performance and projected outlook. Time periods include an average look-back of three years with an emphasis on the past four quarters and a forward look of one to five years. With a Sabrient Earnings Score of 60.5, Haemonetics is marginally lower than the average of its industry group, which has a Sabrient Earnings Score of 69.4.

Balance Sheet Score: 85.8




The Sabrient Balance Sheet Score measures a company's liquidity and debt issues, as well as receivables and inventory quality. This score is used to assess relative risk associated with a stock: the lower the score, most likely the higher the inherent risk. With a Sabrient Balance Sheet Score of 85.8, Haemonetics is moderately higher than the average of its industry group, which carries a Sabrient Balance Sheet Score of 72.0.

Fundamental Score: 35.0



The Sabrient Fundamental Score is the broad measure of a company's financial health, including its balance sheet, cash flow, revenue, and earnings quality. With a Sabrient Fundamental Score of 35.0, Haemonetics is moderately lower than the average of its industry group, which carries a Sabrient Fundamental Score of 51.6.

Timeliness Score: 16.8



The Sabrient Timeliness Score is an assessment of a stock's short and long-term price strength as determined by various chart-based indicators and measures of group momentum and relative price performance. With a Sabrient Timeliness Score of 16.8, Haemonetics is considerably lower than the average of its industry group, which carries a Sabrient Timeliness Score of 41.8.

Peer Analysis


This table compares HAE with other similar-sized companies in the same industry group, focusing on Sabrient's growth, momentum and value scores, which represent the three main investing styles. The Peer Analysis chart compares HAE's 2-year total return with the average 2-year total return of these companies.




Historical Sabrient Scores

The recent histories of key Sabrient scores provide insight into the stock's trends -- whether they are increasing or decreasing in strength in a particular area or simply holding steady. The Sabrient scores are percentile rankings from 0 to 99.9, with higher scores better. Keep in mind that Sabrient ratings may seem inconsistent with a simple average of these key scores because a weighted average of several key scores is used to quantify the relative likelihood of upside or downside price action.


Growth Score: 75.1




Value Score: 36.0




Momentum Score: 17.6




Earnings Score: 60.5




Balance Sheet Score: 85.8



Fundamental Score: 35.0



Timeliness Score: 16.8



Sabrient Analysis continued from Page 1

- **Best Performing Filters:** To determine the likelihood of near-term performance, Sabrient builds and backtests "Smart Filters" to establish which caps, styles and attributes are drawing a premium in today's market. Currently, the three most predictive filters for the relevant segment are:

Primary Value Filter: The Primary Value Filter measures key growth and valuation ratios, both long-term and short-term. It is currently one of our best-performing filters, showing a significant premium to its mid-cap benchmark for the past three months. HAE scores 36.9 for this filter.

Financial Quality Filter: The Financial Quality Filter assesses a company's financial health, emphasizing cash flow, along with projections for bottom-line and recent top-line growth. It is currently among Sabrient's best performing filters in the mid-cap market. HAE scores 19.1 for this filter.

Turnaround Filter: The Turnaround Filter gives high scores to stocks that exhibit low relative valuations and relatively stagnant EPS growth over the last three years, but have favorable EPS projections that have not yet been rewarded by the market. The filter dramatically outperformed its mid-cap benchmark during the last three months. HAE scores 43.1 for this filter.

In summary HAE's Buy rating is based on the stock's overall profile as determined by Sabrient's stock selection filters. This analysis should be considered in light of the recent behavior of the market, discussed below.

What the Market Wants: May 2009

[Note: 'What the Market Wants' is based on the market behavior and Sabrient's filter backtesting results for the previous month.]

THE BEAR IS DEAD . . . LONG LIVE THE BULL?

By David Brown, Chief Market Strategist

(May 4, 2009 5:45 pm PST)

Perhaps not. Many don't consider the birth of the bull until the S&P 500 index crosses its 200-day moving average, and that milestone is still a short distance away. So perhaps we have a baby bull and a very wounded bear, but keep in mind that this is one of the most ferocious bears in history. One swipe of his claw can knock a baby bull off his feet.

That said, April was a glorious month, with the market blooming almost every week. The Russell Midcap Value was up an awesome 19.1% for the month, and the Nasdaq was up 12.35%. Indeed, every index was up double-digits, except for the Dow, up 7.4%, and the S&P 500, barely missing two digits at 9.4%.

Similarly, the last three months show everybody in the black, led by Mid-cap Growth (+15.6%) and the Nasdaq (+16.3%). The majority of the six-month numbers are still in the red, as are the 12-months numbers. The year-to-date performance is mixed between positive and negative, but is led by Mid-cap Growth.

With regard to styles, over the past month value slightly outperformed growth in most caps, but still trails over the past quarter by fairly wide margins.

For the most part, corporate earnings have surprised to the positive for the first quarter. Especially surprising were a number of banks that significantly beat their numbers and posted fairly handsome levels of profit.

Leading indicators, in general, have been better than expected, while lagging indicators such as employment statistics remain in dismal territory.

We should still be wary of economic pitfalls because technically, we are still in a recession. There could be negative economic surprises from the upcoming bank stress tests results and from future problems related to consumer debt levels, including credit cards.

Nonetheless, the near-term outlook for the market remains positive as money continues to flow back into equities, and short-covering fuels strong rallies among previously weak stocks. It is interesting to note, however, that despite the strong market rally over the last three months, market valuations in general remain slightly below the bottom of the 1987 crash.

Growth metrics remain the clear favorite, but the market's rise has fueled more interest in reasonable valuations, as evidenced by the improving results of the value style over the past month. The prudent investor will carefully build his portfolio from among the strong valuations that remain available.

Next update: First week of June.

Company Description

Haemonetics Corporation designs, manufactures, and markets automated blood processing systems and single use consumables for blood donors and surgical patients. The company's donor products and services include plasma systems that automate the collection of plasma from donors; blood bank systems comprising MCS brand system, which automates the collection of platelets and other blood components from volunteer donors, and ACP brand systems that automate the process used to freeze, thaw, and wash red blood cells, as well as manufacture sterile intravenous solutions; red cell systems, which automates the collection of red cells from volunteer donors; and services and programs related to blood supply chain, such as LEAN and Six Sigma consulting, as well as InSight, a program application supporting blood center resource allocation and utilization. Its patient products and services comprise blood salvage systems that allow for the recovery, segregation, and washing of red cells from blood lost by a patient during or after surgery; SmartSuction product, which clears blood and debris from the surgical field; Thrombelastograph Hemostasis Analyzer system, a diagnostic tool for surgeons; and blood management consulting. Haemonetics Corporation also provides information technology platforms and technical support for donor recruitment and for operations of blood and plasma collection centers, and manages back office functions and distribution at plasma fractionation facilities; business solutions to support process excellence, donor recruitment, business design, and blood management efforts; and hospital blood management assessment tools to hospitals. The company markets its products through direct sales force, independent distributors, and agents in the United States, Europe, Japan, and Asia. Haemonetics Corporation was founded in 1971 and is based in Braintree, Massachusetts.

About Sabrient

Sabrient Systems is an independent research firm providing statistical analysis of a company's fundamental data to investment professionals. We use a computer-driven, quantitative methodology to identify stocks that appear poised to outperform or underperform the market.

The Sabrient methodology was developed by an experienced research team led by David Brown, a former NASA scientist and retired CEO of Telescan and designer of its premier stock search program, ProSearch. The research team employs a scientific approach to the creation and testing of multi-factor filters. Each filter targets a key area of traditional stock analysis, including value, growth, momentum, fundamentals, earnings, balance sheet, and group strength. Using an adaptive process, filters are continually tested and monitored to ensure that only the best performing filters are at work.

Sabrient's ratings begin with an extraction process in which each of the few best-performing filters scans the universe of equities to identify stocks having certain compelling attributes sought, but not sufficiently rewarded, by the current market. Then, a composite scoring system employs a broader set of "weighting" filters to rank the extracted stocks. To support individual investors, Sabrient uses the same sophisticated methodology to provide individual stock reports on a universe of approximately 5,600 stocks.

Sabrient regularly tests the performance of its stock selections, using its primary list of published rankings and statistical techniques it believes appropriate. These recommendations have consistently outperformed relevant benchmarks across a broad range of investing styles, market caps, time frames and market conditions, demonstrating the robustness of Sabrient's proprietary methodology. While past performance is no guarantee of future results, Sabrient believes it can maintain its strong performance through its rigorous, scientific approach to filter construction and ongoing backtesting within a dynamic and adaptive composite scoring system.

For more information on Sabrient and its performance, go to www.sabrient.com

Disclaimer

Sabrient SmartStock™ research is provided for informational purposes only. It is neither a solicitation to buy nor an offer to sell these securities. The report is based upon data from sources believed to be reliable, but Sabrient makes no representation as to the data's adequacy, accuracy, completeness or timeliness. The report does not address individual investment objectives or financial situations. The analysis used in preparing these reports may also be used in the preparation of other research products which may reflect distinct investment objectives. Sabrient accepts no liability for any loss arising from any use of this report.

This report is based solely on mathematical calculations and does not reflect any bias of individual analysts. Sabrient provides no investment banking, consulting or other services to the subject company of this report. No Sabrient employee is on the Board of Directors of the subject company, and no one at the subject company serves on the Board of Directors of Sabrient Systems. Sabrient or its employees may have long or short positions in the securities or other related investments of the company mentioned herein, but never more than one percent (1%) of the outstanding shares of any company covered by Sabrient. No part of this document may be reproduced without the written permission of Sabrient Systems.